Claims
- 1. Method of treating retroviral infections in a mammal comprising administering to said mammal:
- (a) an effective amount of a first retroviral protease inhibitor; and
- (b) an effective amount of a second retroviral protease inhibitor wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor.
- 2. A method of treating a retroviral infection in a mammal comprising administering retroviral protease inhibitors to said mammal in a pharmaceutically effective amount, said retroviral protease inhibitors consisting of a first retroviral protease inhibitor and a second retroviral protease inhibitor) wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor, and wherein said first and second inhibitors are selected from the group consisting of:
- N-(2(R)-Hydroxy-1(S) -indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-1(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide;
- N-tert-Butyl decahydro-2-[2(R)-hydroxy-4-phenyl-3(s)-[[N-(2-quiolylcarbonyl)-L-asparaginyl]amino]butyl](4aR, 8aS)-isoquinoline-3(S) -carboxamide;
- (2S, 3R, 4S, 5S)-2,5-Bis-[N-[N-[[N-methyl-N-(2-pyridinylmethyl)amino]carbonyl]valinyl]amino]-3,4-dihydroxy-1,6-diphenylhexane;
- (2S, 3S, 5S)-5-[N-[N-[N-[N-methyl-N[(2-isopropyl-4-thiazolyl)methyl]amino)carbonyl]valinyl]amino]-2-[N-[(5-thiazolyl)methoxycarbonyl]amino]-3-hydroxy-1,6-diphenylhexane;
- N-tert-Butyl decahydro-2-[2(R)-hydroxy4-(phenylthio)-3(S)-[N-[(2-methyl-3-hydroxyphenyl)carbonyl]amino]butyl]-(4aR, 8aS)-isoquinoline-3(S)-carboxamide;
- [4R-(4.alpha., 5.alpha., 6.beta. 7.beta.)]-1,3-bis](3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one;
- N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-phenylmethyl)propyl]-2S-[[(pyrrolidin-1-yl)acetyl]amino]-3,3-dimethylbutanamide;
- N-[2R-hydroxy-3-[(2-methylpropyl)[(1,3-benzodioxol-5-yl) sulfonyl]amino]-1S-)phenylmethyl)propyl]-2S-methyl-3-(methylsulfonyl)propanamide;
- [1S-[1R"(R"), 2S"]]-N-[2-hydroxy-3-[N.sup.1 -(2-methylpropyl)-N.sup.1 -(4methoxyphenylsulfonyl)amino]-1-(phenylmethyl) propyl]-2-methyl-3-(methylsulfonyl)propanamide;
- 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl) amino]2S-(phenylmethyl)propyl]-3,3-dimethylbutanamide; and
- (2R, 3S)-3-(N-methylaminoacetyl-L-tert-butylglycinyl)amino-1-(N-isoanyl-N-(tert-butylcarbamoyl))amino-4-phenyl-2-butanol.
- 3. Method of claim 1 further comprising administration of at least one antiviral agent other than a protease inhibitor.
- 4. Method of claim 3 wherein said antiviral agent is a nucleoside analog, nonnucleoside reverse transcriptase inhibitor, tat antagonist or glycosidase inhibitor.
- 5. Method of claim 4 wherein said nucleoside analog is AZT, DDI, DDC, 3TC, D4T or PMEA and said glycosidase inhibitor is castanospermine or N-butyl-1-deoxynojirmycin.
- 6. Method of claim 1 wherein said mammal is a human, monkey or cat.
- 7. Method of claim 1 wherein said retrovirus is HIV or HTLV.
- 8. Method of claim 7 wherein said retrovirus is HIV-1 or HIV-2.
Parent Case Info
This is a continuation of application Ser. No. 08/253,638 filed Jun. 3, 1984 (now abandoned).
US Referenced Citations (13)
Foreign Referenced Citations (7)
Number |
Date |
Country |
0337714A2 |
Oct 1989 |
EPX |
342541A2 |
Nov 1989 |
EPX |
346847 |
Dec 1989 |
EPX |
346847A2 |
Dec 1989 |
EPX |
0393445A2 |
Oct 1990 |
EPX |
0402646A1 |
Dec 1990 |
EPX |
0 541 168 A1 |
May 1993 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
253638 |
Jun 1994 |
|